Sanofi touts head-to-head comparison of long-acting insulin products

Sanofi‘s (NYSE:SNY) long-acting insulin glargine, Toujeo, met the primary objective of a head-to-head trial comparing it to Novo Nordisk‘s (NYSE:NVO) insulin degludec, Tresiba, the company reported today.

The insulin-maker said it plans to report full results from the Bright trial sometime next year. The study’s primary objective was to determine if Toujeo had a similar effect on blood sugar levels compared to insulin degludec.

Get the full story at our sister site, Drug Delivery Business News.

The post Sanofi touts head-to-head comparison of long-acting insulin products appeared first on MassDevice.

from MassDevice http://ift.tt/2kkN0Jc